Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls – PubMed Black Hawk Supplements
BLACK HAWK: High quality lions mane supplement for sexual health
Published article
Psilocybin microdosing involves repeated self-administration of mushrooms containing psilocybin at doses small enough to not impact regular functioning. Microdose practices are diverse and include combining psilocybin with substances such as lion’s mane mushrooms (Hericium erinaceus; HE) and niacin (vitamin-B3). Public uptake of microdosing has outpaced evidence, mandating further prospective research. Using a naturalistic, observational design, we followed psilocybin microdosers (n = 953) and…
Black Hawk Supplements, best supplements in the UK
Observational Study
Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls
Joseph M Rootman et al. Sci Rep. .
Erratum in
-
Rootman JM, Kiraga M, Kryskow P, Harvey K, Stamets P, Santos-Brault E, Kuypers KPC, Walsh Z. Rootman JM, et al. Sci Rep. 2022 Jul 28;12(1):12925. doi: 10.1038/s41598-022-17428-0. Sci Rep. 2022. PMID: 35902723 Free PMC article. No abstract available.
Abstract
Psilocybin microdosing involves repeated self-administration of mushrooms containing psilocybin at doses small enough to not impact regular functioning. Microdose practices are diverse and include combining psilocybin with substances such as lion’s mane mushrooms (Hericium erinaceus; HE) and niacin (vitamin-B3). Public uptake of microdosing has outpaced evidence, mandating further prospective research. Using a naturalistic, observational design, we followed psilocybin microdosers (n = 953) and non-microdosing comparators (n = 180) for approximately 30 days and identified small- to medium-sized improvements in mood and mental health that were generally consistent across gender, age and presence of mental health concerns, as we all as improvements in psychomotor performance that were specific to older adults. Supplementary analyses indicated that combining psilocybin with HE and B3 did not impact changes in mood and mental health. However, among older microdosers combining psilocybin, HE and B3 was associated with psychomotor improvements relative to psilocybin alone and psilocybin and HE. Our findings of mood and mental health improvements associated with psilocybin microdosing add to previous studies of psychedelic microdosing by using a comparator group and by examining the consistency of effects across age, gender, and mental health. Findings regarding the combination of psilocybin, HE and B3 are novel and highlight the need for further research to confirm and elucidate these apparent effects.
© 2022. The Author(s).
Conflict of interest statement
Joseph Rootman has received research funding from Quantified Citizen Technologies, which is a company that produces software for decentralized mobile research that provided the data collection platform for this study. Maggie Kiraga is an employee of Quantified Citizen. Kalin Harvey is co-founder and CTO of Quantified Citizen, co-founder of the Psychedelic Data Project, co-founder and director of the Ketamine Assisted Therapy Association of Canada, and he is also an Investor in MycoMedica Life Sciences. Pamela Kryskow is a member of the clinical advisory board of Numinus Wellness, which is a company that provides psychedelic psychotherapy services. Pamela Kryskow is compensated for this role with Numinus stock. She is a volunteer consultant for Nectara. She is a co-founder of MycoMedica Life Sciences and on the Scientific & Medical Advisory Board. Paul Stamets is an investor in Quantified Citizen, MycoMedica Life Sciences, PBC and owns Fungi Perfecti, LLC which sells Lion Mane supplements. He is an applicant on pending patents combining psilocybin mushrooms, Lions Mane mushrooms and niacin. Eesmyal Santos-Brault is co-founder and CEO of Quantified Citizen, co-founder of the Psychedelic Data Project and an Investor in MycoMedica Life Sciences. Kim PC Kuypers is a principal investigator on research projects, the present study not included, that are sponsored by Mindmed and Silopharma which are companies that are developing psychedelic medicines, and she is a paid member of the scientific advisory board of Clerkenwell Health. Zach Walsh is in a paid advisory relationship with Numinus Wellness and Entheotech BioMedical regarding the medical development of psychedelics, and is a member of the Advisory Board of the Multidisciplinary Association for Psychedelic Studies (MAPS) Canada and MycoMedica Life Sciences.
Figures
Similar articles
-
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research.
Polito V, Liknaitzky P. Polito V, et al. J Psychopharmacol. 2024 Aug;38(8):701-711. doi: 10.1177/02698811241254831. Epub 2024 Jun 14. J Psychopharmacol. 2024. PMID: 38877715 Free PMC article. Review.
-
Rootman JM, Kryskow P, Harvey K, Stamets P, Santos-Brault E, Kuypers KPC, Polito V, Bourzat F, Walsh Z. Rootman JM, et al. Sci Rep. 2021 Nov 18;11(1):22479. doi: 10.1038/s41598-021-01811-4. Sci Rep. 2021. PMID: 34795334 Free PMC article.
-
Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
Rosenbaum D, Weissman C, Anderson T, Petranker R, Dinh-Williams LA, Hui K, Hapke E. Rosenbaum D, et al. J Psychopharmacol. 2020 Jun;34(6):612-622. doi: 10.1177/0269881120908004. Epub 2020 Feb 28. J Psychopharmacol. 2020. PMID: 32108529
-
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.
Anderson T, Petranker R, Rosenbaum D, Weissman CR, Dinh-Williams LA, Hui K, Hapke E, Farb NAS. Anderson T, et al. Psychopharmacology (Berl). 2019 Feb;236(2):731-740. doi: 10.1007/s00213-018-5106-2. Epub 2019 Jan 2. Psychopharmacology (Berl). 2019. PMID: 30604183
-
Microdosing with classical psychedelics: Research trajectories and practical considerations.
Wong A, Raz A. Wong A, et al. Transcult Psychiatry. 2022 Oct;59(5):675-690. doi: 10.1177/13634615221129115. Epub 2022 Oct 31. Transcult Psychiatry. 2022. PMID: 36317302 Review.
Cited by
-
Psilocybin for the treatment of Alzheimer’s disease.
Zheng S, Ma R, Yang Y, Li G. Zheng S, et al. Front Neurosci. 2024 Jul 10;18:1420601. doi: 10.3389/fnins.2024.1420601. eCollection 2024. Front Neurosci. 2024. PMID: 39050672 Free PMC article. Review.
-
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research.
Polito V, Liknaitzky P. Polito V, et al. J Psychopharmacol. 2024 Aug;38(8):701-711. doi: 10.1177/02698811241254831. Epub 2024 Jun 14. J Psychopharmacol. 2024. PMID: 38877715 Free PMC article. Review.
-
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.
Metaxa AM, Clarke M. Metaxa AM, et al. BMJ. 2024 May 1;385:e078084. doi: 10.1136/bmj-2023-078084. BMJ. 2024. PMID: 38692686 Free PMC article.
-
Breeksema JJ, Niemeijer A, Krediet E, Karsten T, Kamphuis J, Vermetten E, van den Brink W, Schoevers R. Breeksema JJ, et al. Sci Rep. 2024 Feb 5;14(1):2929. doi: 10.1038/s41598-024-53188-9. Sci Rep. 2024. PMID: 38316896 Free PMC article. Clinical Trial.
-
Rouaud A, Calder AE, Hasler G. Rouaud A, et al. J Psychopharmacol. 2024 Mar;38(3):217-224. doi: 10.1177/02698811231225609. Epub 2024 Jan 12. J Psychopharmacol. 2024. PMID: 38214279 Free PMC article. Review.
References
-
- Carod-Artal, F. J. Hallucinogenic drugs in pre-Columbian Mesoamerican cultures (English edition). (Neurolia, 2015). – PubMed
-
- Nye, B. C. Microdosing: The people taking LSD with their breakfast. BBC News. BBC News (2017). Available at: https://www.bbc.com/news/health-39516345.
-
- Williams, A. How LSD Saved One Woman’s Marriage. New York Times (2017).
Publication types
MeSH terms
Substances
BLACK HAWK: Best lions mane supplement for women
Read the original publication: